Syros Pharmaceuticals (NASDAQ: SYRS) reported Q3 EPS of ($1.43), $0.29 worse than the analyst estimate of ($1.14). Revenue for the quarter came in at $3.76 million versus the consensus estimate of $3.94 million.

For earnings history and earnings-related data on Syros Pharmaceuticals (SYRS) click here.